TRAJENTA®

Linagliptin

 

TRAJENTA®

Resources

Browse our engaging and informative collection of resources to learn more about TRAJENTA®.

Quick links

Quick links

Management of type 2 diabetes in the elderly and frail.

Management of type 2 diabetes in the elderly and frail

Watch this interactive video where Dr Sarah Jarvis discuss the ideal glycaemic target and simplifying the management of type 2 diabetes for the elderly and frail as well as the practicalities of treatment with DDP-4 inhibitors.

Developed and funded by Boehringer Ingelheim

T2 Discussions

Read more
The burden of hypoglycaemia in adults
Video

The burden of hypoglycaemia in adults

November, 20226:56 m
Read more
NICE guidance (NG28) – the management of type 2 diabetes in adults
Video

NICE guidance (NG28) – the management of type 2 diabetes in adults

August, 202211:46 m
Read more
The impact of clinical inertia on the achievement of treatment targets in adults with type 2 diabetes: Summary
Video

The impact of clinical inertia on the achievement of treatment targets in adults with type 2 diabetes: Summary

August, 202314:56 m

Build your Knowledge

Read more
Check your knowledge of the correct DPP-4 inhibitor dose as per summary of product characteristics.
Game

Check your knowledge of the correct DPP-4 inhibitor dose as per summary of product characteristics.

November 2022Play > (desktop devices only)

Downloadable Resources

See More
Metabolism TRAJENTA® (linagliptin) DPP-4 inhibitor with 2 cardiovascular outcome trials
Resource

Metabolism TRAJENTA® (linagliptin) DPP-4 inhibitor with 2 cardiovascular outcome trials

See More
See More
The impact of clinical inertia on the achievement of treatment targets in adults with type 2 diabetes: Summary
Resource

The impact of clinical inertia on the achievement of treatment targets in adults with type 2 diabetes: Summary

See More

Patient Resources

Read more
Getting started on TRAJENTA® (linagliptin)
Video

Getting started on TRAJENTA® (linagliptin)

June, 20222:41 m
TRAJENTA® (linagliptin) patient FAQ leaflet
Resource

TRAJENTA® (linagliptin) patient FAQ leaflet

See More
TRAJENTA® (linagliptin) patient FAQ leaflet - Polish
Resource

TRAJENTA® (linagliptin) patient FAQ leaflet - Polish

See More
TRAJENTA® (linagliptin) patient FAQ leaflet - Hindi
Resource

TRAJENTA® (linagliptin) patient FAQ leaflet - Hindi

See More
TRAJENTA® (linagliptin) patient FAQ leaflet - Urdu
Resource

TRAJENTA® (linagliptin) patient FAQ leaflet - Urdu

See More
TRAJENTA® (linagliptin) patient FAQ leaflet - Gujarati
Resource

TRAJENTA® (linagliptin) patient FAQ leaflet - Gujarati

See More
TRAJENTA® (linagliptin) patient FAQ leaflet - Bengali
Resource

TRAJENTA® (linagliptin) patient FAQ leaflet - Bengali

See More
TRAJENTA® (linagliptin) patient FAQ leaflet - Punjabi
Resource

TRAJENTA® (linagliptin) patient FAQ leaflet - Punjabi

See More

PC-GB-106991 V5

October 2023

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found atwww.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.